KPTI supply chain intelligence for Karyopharm Therapeutics Inc.: verified suppliers, customers, debt relationships, acquisitions, and ownership data.
Data compiled by Redley Lamar · ChainSifter Intelligence
| Ticker | Name | Confidence | Evidence |
|---|---|---|---|
| THIRD-PARTY-CONTRACT-MANUFACTURERS | THIRD-PARTY-CONTRACT-MANUFACTURERS | 92% | We currently rely, and expect to continue to rely, on third-party contract manufacturers to manufacture our products and product candidates for our commercial and clinical use. |
| ADVERTISING-AGENCIES | ADVERTISING-AGENCIES | 90% | We employ third-party vendors, such as advertising agencies, market research firms and suppliers of marketing and other sales support-related services, to assist with our commercial activities. |
| MARKET-RESEARCH-FIRMS | MARKET-RESEARCH-FIRMS | 90% | We employ third-party vendors, such as advertising agencies, market research firms and suppliers of marketing and other sales support-related services, to assist with our commercial activities. |
| ORANY | ORANY | 72% | respond to the product candidate to obtain pre-market approval (“PMA”) simultaneously with approval of the therapeutic product candidate. The PMA process, including the gathering of clinical and prec… |
| ORANY | ORANY | 72% | Reciprocal relationship from ORANY graph: Reciprocal relationship from KPTI graph: respond to the product candidate to obtain pre-market approval (“PMA”) simultaneously with approval of the therapeut… |
| Ticker | Name | Confidence | Evidence |
|---|---|---|---|
| PHARMACY-BENEFIT-MANAGERS | PHARMACY-BENEFIT-MANAGERS | 85% | A number of states, for example, require drug manufacturers and other entities in the drug supply chain, including health carriers, pharmacy benefit managers, wholesale distributors, to disclose info… |
| ORANY | ORANY | 72% | respond to the product candidate to obtain pre-market approval (“PMA”) simultaneously with approval of the therapeutic product candidate. The PMA process, including the gathering of clinical and prec… |
| ORANY | ORANY | 72% | Reciprocal relationship from ORANY graph: Reciprocal relationship from KPTI graph: respond to the product candidate to obtain pre-market approval (“PMA”) simultaneously with approval of the therapeut… |
| ANTENGENE-CORPORATION-CO-LTD | ANTENGENE-CORPORATION-CO-LTD | 62% | ecoverability of our inventory each reporting period and write-down any inventory that has become obsolete, that has a cost basis in excess of its estimated realizable value, or that is not expected … |
| HEALTHCARE-ROYALTY-PARTNERS | HEALTHCARE-ROYALTY-PARTNERS | 62% | ortized cost basis. Any impairment that is not related to a credit loss is recognized in other comprehensive income (loss). Changes in the allowance for credit losses are recorded as a provision for … |
| Instrument | Description | Confidence | Evidence |
|---|---|---|---|
| KPTI-DEBT-10565 | Warrants outstanding: 0.0001 | 90% | xbrl warrant detail from xbrl 2026-03-31. |
| KPTI-DEBT-10566 | Xbrl Convertible | 90% | xbrl convertible detail from xbrl 2025-12-31. |
| KPTI-DEBT | Debt stack $296.7M | 90% | Market cache reports total debt of $296.7M. |
| Holder | Name | Confidence | Evidence |
|---|---|---|---|
| KPTI-OWNER-EXOME-ASSET-MANAGEMENT-LLC | Exome Asset Management LLC | 95% | 13F/ownership overlay lists Exome Asset Management LLC ; shares held 295,541; ownership 1.61%; value $1.6M; as of 2025-12-31. |
| KPTI-OWNER-VANGUARD-GROUP-INC | Vanguard Group Inc | 95% | 13F/ownership overlay lists Vanguard Group Inc; shares held 559,619; ownership 3.05%; value $3.1M; as of 2025-12-31. |
| KPTI-OWNER-SOLEUS-CAPITAL-MANAGEMENT-L-P | Soleus Capital Management, L.P. | 95% | 13F/ownership overlay lists Soleus Capital Management, L.P.; shares held 440,000; ownership 2.40%; value $2.4M; as of 2025-12-31. |
| KPTI-OWNER-ADAGE-CAPITAL-PARTNERS-GP-L-L-C | Adage Capital Partners GP L.L.C. | 95% | 13F/ownership overlay lists Adage Capital Partners GP L.L.C.; shares held 421,322; ownership 2.30%; value $2.3M; as of 2025-12-31. |
| KPTI-OWNER-DAVIDSON-KEMPNER-CAPITAL-MANAGEMENT-LP | Davidson Kempner Capital Management LP | 95% | 13F/ownership overlay lists Davidson Kempner Capital Management LP; shares held 310,020; ownership 1.69%; value $1.7M; as of 2025-12-31. |
| KPTI-OWNER-OPALEYE-MANAGEMENT-INC | Opaleye Management Inc. | 95% | 13F/ownership overlay lists Opaleye Management Inc.; shares held 930,000; ownership 5.07%; value $5.1M; as of 2025-12-31. |
| KPTI-OWNER-IKARIAN-CAPITAL-LLC | Ikarian Capital, LLC | 95% | 13F/ownership overlay lists Ikarian Capital, LLC; shares held 544,554; ownership 2.97%; value $3.0M; as of 2025-12-31. |
| KPTI-OWNER-T-ROWE-PRICE-INVESTMENT-MANAGEMENT-INC | T. Rowe Price Investment Management, Inc. | 95% | 13F/ownership overlay lists T. Rowe Price Investment Management, Inc.; shares held 1,491,409; ownership 8.13%; value $8.2M; as of 2025-12-31. |
| KPTI-OWNER-AFFINITY-ASSET-ADVISORS-LLC | Affinity Asset Advisors, Llc | 95% | 13F/ownership overlay lists Affinity Asset Advisors, Llc; shares held 889,575; ownership 4.85%; value $4.9M; as of 2025-12-31. |
| KPTI-OWNER-BRAIDWELL-LP | Braidwell LP | 95% | 13F/ownership overlay lists Braidwell LP ; shares held 303,370; ownership 1.65%; value $1.7M; as of 2025-12-31. |
| Ticker | Name | Chain Index | Hops | Relationship Types |
|---|---|---|---|---|
| EYE | National Vision Holdings, Inc. | 100.00 | 2 | |
| ORANY | ORANGE | 100.00 | 1 | ['customer', 'supplier'] |
| VSA | VisionSys AI Inc. | 100.00 | 2 | |
| MRK | Merck & Co., Inc. | 100.00 | 2 | |
| ANL | Adlai Nortye Ltd. | 100.00 | 2 | |
| BBIO | BridgeBio Pharma, Inc. | 100.00 | 2 | |
| IRON | Disc Medicine, Inc. | 100.00 | 2 | |
| KREF | KKR Real Estate Finance Trust Inc. | 100.00 | 2 | |
| SNYNF | Sanofi | 100.00 | 2 | |
| NVSEF | Novartis AG | 100.00 | 2 | |
| D | Dominion Energy, Inc. | 50.00 | 2 | |
| CLNE | Clean Energy Fuels Corp. | 50.00 | 2 | |
| FENC | Fennec Pharmaceuticals Inc. | 50.00 | 2 | |
| EQR | Equity Residential | 50.00 | 2 | |
| CHUC | Charlie's Holdings, Inc. | 50.00 | 2 | |
| AYTU | Aytu BioPharma, Inc. | 50.00 | 2 | |
| AMZE | Amaze Holdings, Inc. | 50.00 | 2 | |
| DFTX | Definium Therapeutics, Inc. | 50.00 | 2 | |
| SCNX | Scienture Holdings, Inc. | 50.00 | 2 | |
| CANF | Can-Fite BioPharma Ltd. | 50.00 | 2 |